- Home
- BMRC vs TSHA Comparison
BMRC vs TSHA Comparison
Compare BMRC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- TSHA
- Stock Information
- Founded
- BMRC 1989
- TSHA 2019
- Country
- BMRC United States
- TSHA United States
- Employees
- BMRC N/A
- TSHA N/A
- Industry
- BMRC Major Banks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- TSHA Health Care
- Exchange
- BMRC Nasdaq
- TSHA Nasdaq
- Market Cap
- BMRC 394.5M
- TSHA 356.7M
- IPO Year
- BMRC N/A
- TSHA 2020
- Fundamental
- Price
- BMRC $19.94
- TSHA $1.27
- Analyst Decision
- BMRC Strong Buy
- TSHA Strong Buy
- Analyst Count
- BMRC 3
- TSHA 8
- Target Price
- BMRC $28.00
- TSHA $6.63
- AVG Volume (30 Days)
- BMRC 63.2K
- TSHA 2.4M
- Earning Date
- BMRC 04-28-2025
- TSHA 05-13-2025
- Dividend Yield
- BMRC 4.89%
- TSHA N/A
- EPS Growth
- BMRC N/A
- TSHA N/A
- EPS
- BMRC N/A
- TSHA N/A
- Revenue
- BMRC $67,983,000.00
- TSHA $8,333,000.00
- Revenue This Year
- BMRC $63.26
- TSHA N/A
- Revenue Next Year
- BMRC $9.68
- TSHA N/A
- P/E Ratio
- BMRC N/A
- TSHA N/A
- Revenue Growth
- BMRC N/A
- TSHA N/A
- 52 Week Low
- BMRC $14.11
- TSHA $1.17
- 52 Week High
- BMRC $27.11
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- BMRC 24.49
- TSHA 33.64
- Support Level
- BMRC $21.51
- TSHA $1.17
- Resistance Level
- BMRC $22.50
- TSHA $1.87
- Average True Range (ATR)
- BMRC 0.90
- TSHA 0.17
- MACD
- BMRC -0.12
- TSHA -0.06
- Stochastic Oscillator
- BMRC -1.65
- TSHA 12.18
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.